The stimulator of interferon genes (STING) cellular signaling pathway is a promising target
for cancer immunotherapy. Activation of the intracellular STING protein triggers the …

Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …

Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates
antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We …

Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …

The often immune-suppressive tumor microenvironment (TME) may hinder immune evasion
and response to checkpoint blockade therapies. Pharmacological activation of the STING …

Although immunotherapy such as immune checkpoint inhibitors has shown promising
efficacy in cancer treatment, the responsiveness among patients is relatively limited …

The tumor-associated vasculature imposes major structural and biochemical barriers to the
infiltration of effector T cells and effective tumor control. Correlations between stimulator of …

Stimulator of interferon genes (STING) pathway is the key innate immune pathway involving
in cancer immunity. Emerging new molecules and drug delivery systems have made …

Immune checkpoint inhibitors (ICIs) have displayed potential efficacy in triple-negative
breast cancer (TNBC) treatment, while only a minority of patients benefit from ICI therapy …

The activation of STING in cancer cells is conducive to inducing apoptosis of cancer cells
and activating immune responses for immunotherapy by improving antigen presentation …